We have established a manufacturing system for a Vero cell-derived inactivated Japanese encephalitis vaccine at a 500l scale. The production system involves expansion of Vero cells using microcarrier, followed by virus infection. Except for an additional purification step, the downstream purification processes are similar to those used for the current mouse brain-derived vaccine; cell removal, concentration and removal of low-molecular weight impurities by membrane filtration, formalin-inactivation, sucrose density gradient ultracentrifugation, and Sulfate-Cellulofine column chromatography are conducted. The antigen obtained from the manufacturing system was highly purified and its physico-chemical and immunological properties were comparable with those of antigen derived from mouse brains. Our system is very simple and could be easily scaled-up to allow vaccine production at a several thousand litre scale.

Download full-text PDF

Source
http://dx.doi.org/10.1006/biol.2002.0345DOI Listing

Publication Analysis

Top Keywords

vero cell-derived
8
cell-derived inactivated
8
inactivated japanese
8
japanese encephalitis
8
encephalitis vaccine
8
manufacturing system
8
development vero
4
vaccine
4
vaccine established
4
established manufacturing
4

Similar Publications

An accumulated mutation gained in mosquito cells enhances Zika virus virulence and fitness in mice.

J Virol

November 2024

State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing, China.

Unlabelled: Zika virus (ZIKV) remains a significant public health threat worldwide. A number of adaptive mutations have accumulated within the genome of ZIKV during global transmission, some of which have been linked to specific phenotypes. ZIKV maintains an alternating cycle of replication between mosquitoes and vertebrate hosts, but the role of mosquito-specific adaptive mutations in ZIKV has not been well investigated.

View Article and Find Full Text PDF

Mesenchymal stem cell (MSC)-derived extracellular vesicles (EVs) have shown anti-inflammatory potential in multiple inflammatory diseases. In the March 2022 issue of the Journal of Extracellular Vesicles, it was shown that EVs from human MSCs can suppress severe acute respiratory distress syndrome, coronavirus 2 (SARS-CoV-2) replication and can mitigate the production and release of infectious virions. We therefore hypothesized that MSC-EVs have an anti-viral effect in SARS-CoV-2 infection in vivo.

View Article and Find Full Text PDF

Anti-SARS-CoV-2 gapmer antisense oligonucleotides targeting the main protease region of viral RNA.

Antiviral Res

October 2024

Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan; Department of Virology II, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan; Department of Applied Biological Sciences, Tokyo University of Science, Noda, 278-8510, Japan; MIRAI, JST, Tokyo, 102-0076, Japan. Electronic address:

Article Synopsis
  • Emerging respiratory viruses like SARS-CoV-2 pose a global risk, prompting the need for new antiviral strategies, particularly through the use of gapmer antisense oligonucleotides (ASOs).
  • Researchers synthesized about 300 ASOs targeting different regions of the SARS-CoV-2 RNA and effectively identified ASO#41, which inhibited viral replication and reduced infection-related cell damage.
  • ASO#41 demonstrated strong antiviral activity against multiple variants of SARS-CoV-2 in lab models and showed promise in mice, indicating its potential as a targeted treatment approach for respiratory viruses.
View Article and Find Full Text PDF

Suppression of HSV-1 infection and viral reactivation by CRISPR-Cas9 gene editing in 2D and 3D culture models.

Mol Ther Nucleic Acids

September 2024

Center for Neurovirology and Gene Editing, Department of Microbiology, Immunology and Inflammation, Temple University Lewis Katz School of Medicine, Philadelphia, PA 19140, USA.

Although our understanding of herpes simplex virus type 1 (HSV-1) biology has been considerably enhanced, developing therapeutic strategies to eliminate HSV-1 in latently infected individuals remains a public health concern. Current antiviral drugs used for the treatment of HSV-1 complications are not specific and do not address latent infection. We recently developed a CRISPR-Cas9-based gene editing platform to specifically target the HSV-1 genome.

View Article and Find Full Text PDF

This study was to evaluate the sufficient safety and effect of the novel influenza vaccine program. It prepared new reassortant influenza virus, with high yield on Vero cells. According to the plaque counting, one dose LAIV was composed with 10 PFU of H1, H3, BY, and BV, respectively.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!